Patheon, a DPx business unit, is a result of the recent transaction between JLL Partners and Royal DSM. Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, and is strengthened by the capabilities of the legacy DSM Pharmaceutical Products business which have been integrated into the business unit. The business unit provides the industry with CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO)business. Patheon now offers process development and cGMP manufacturing of mammalian cell culture products from preclinical development to commercial supply and sterile fill/finish capabilities to the Pharma industry.
You can count on Patheon’s experience to help you evolve your biologic innovation from preclinical stages to the commercial production of a viable product. From having developed over 100 of successful biologic drug substance projects and over 80 biologic dose forms, Patheon has extensive experience ranging from early development to product commercialization. We understand the specific needs of large molecule programs, and through our technical expertise and flexible offering
we help you to successfully bring your product to the market.
Product development is supported by robust site infrastructure including Bioanalytical laboratories (including cell-based assays) and storage of refrigerated and frozen drug products (-20°C and -70°C). Liquid and lyophilized products are effectively managed using minimal amounts of drug substance. Our broad range of capabilities and resources – often within a single site – gives us the flexibility to engineer exactly the right formulation. Patheon offers small and large scale manufacturing for multiple dosage formats in state-of-the-art facilities.
Click here to learn more about our services for your biologic drug substance products and capabilities.